New research tracked subclinical carotid plaque changes over six years and found that plaques with calcification were twice as likely to develop intraplaque hemorrhage, with men showing greater risk for complex plaque progression.
A phase 3 trial of an oral fixed-dose combination of obicetrapib and ezetimibe showed a nearly 50% reduction in LDL cholesterol levels in patients at high risk for heart disease, without added safety concerns.
A new clinical trial is investigating whether removing clots using a modified access point can better prevent post-thrombotic syndrome in patients with extensive deep vein thrombosis.
May’s FDA approvals include the first at-home HPV test, a blood-based Alzheimer’s diagnostic, biosimilars, AI-enabled imaging tools, and novel therapies across cardiology, pulmonology, neurology, gastroenterology, and more.
Conexiant
Daily News
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
Thank you for signing up for the Daily News alerts. You will begin receiving them shortly.
A new clinical trial found that adding mepolizumab to standard inhaled therapy significantly reduced moderate or severe COPD exacerbations in patients with high eosinophil counts, with a 21% lower annual rate and longer time to first flare.
Short sleep, late blood draws, and intense workouts significantly change common cardiovascular biomarkers, suggesting key variables often go unaccounted for in heart risk assessments.
The FDA has approved Abbott’s Tendyne system, the first transcatheter mitral valve replacement for patients with severe mitral annular calcification who are ineligible for open-heart surgery.